Navigation Links
Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
Date:4/17/2008

n the market for infected diabetic foot ulcers, we view this phase 2 program as a significant step towards treating and potentially preventing this highly serious and widely prevalent complication of diabetes."

About Infected Diabetic Foot Ulcers

According to the Centers for Disease Control and Prevention (CDC), the estimated incidence of diabetes in the US exceeds 1.5 million new cases annually, with an overall prevalence of 20.8 million people, or 7% of the US population. By 2030, the International Diabetes Federation predicts that the Global prevalence of diabetes will almost double from 193 million people (estimated in 2003) to 366 million.

An estimated 15% of patients with diabetes will develop a lower extremity ulcer during the course of their disease. According to a large prospective study, approximately 7% of diabetic patients with foot ulcers will require an amputation. Diabetic foot is the most common cause of nontraumatic lower extremity amputations in the US and Europe, with an average of 82,000 amputations per year in the US costing an estimated $1.6 billion annually. The estimated cost of foot ulcer care in the US ranges from $4,595 per ulcer episode to more than $28,000, for the 2 years post diagnosis. The total annual cost of foot ulcer care in the US has been estimated to be as high as $5 billion.

About Innocoll, Inc.

Innocoll is a privately held, biopharmaceutical company focused on biodegradable surgical implants and topically applied healthcare products. It develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, CollaRx(R) and Liquicoll(R). Innocoll 's lead product, Gentamicin Surgical Implant for the treatment and prevention of surgical site infections, is approved for sale in 49 countries in Europe, Latin America, Middle East, Africa and Asia and is marketed under the following trade names; COLLATAMP(R) G, COLLATAMP(R) EG, SULMYCIN(R)
'/>"/>

SOURCE Innocoll Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
2. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
3. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
4. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
5. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
6. ViroPharma Announces Discontinuation of HCV-796 Development
7. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
8. Free Prostate Cancer Seminar in Lake Ridge, VA: Dr. Charles Snuffy Myers Announces Vitamin D Clinical Trials
9. Phreesia Announces Clinical Initiative to Better Manage Symptoms of Parkinsons Disease
10. Cardiums Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack
11. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)...  VentiRx Pharmaceuticals, Inc., a clinical stage ... commercialization of novel Toll-like receptor 8 (TLR8) ... and clinical activities at the company including ... clinical trials and future clinical development efforts. ... Officer Robert Hershberg , M.D., Ph.D. ...
(Date:9/2/2014)... Sept. 2, 2014  BioSpecifics Technologies Corp. (NASDAQ: ... products marketed as XIAFLEX ® in the U.S. and ... President, Tom Wegman , will present at the following ... Rodman & Renshaw 16 th Annual ... Tuesday, September 9, 2014 at 9:10 a.m. EDT ...
(Date:9/2/2014)... OAKS, Calif. , Sept. 2, 2014 ... today announced the submission of a Marketing ... Agency (EMA) via the centralized procedure for ... of adults with melanoma that is regionally ... oncolytic immunotherapy administered as an intralesional injection ...
Breaking Medicine Technology:VentiRx Pharmaceuticals Provides Corporate and Clinical Update 2VentiRx Pharmaceuticals Provides Corporate and Clinical Update 3BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences 2Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 2Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 3Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 4Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 5Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 6
(Date:9/2/2014)... York (PRWEB) September 02, 2014 - ... defined as a class of diagnostic test that analyzes ... The nucleic acids and proteins that belong to individual ... therapy, health condition, or risk of developing a specific ... better known as (MDx) evaluating the new class of ...
(Date:9/2/2014)... A New York City based company ... simple, yet revolutionary, product that will have ... health care costs for Americans. , REMIND-A-CAP™ ... puts control in the user's hands. It's a simple ... next date of intake by simply turning a knob. ...
(Date:9/2/2014)... may help scientists learn why patients with cystic fibrosis ... their lungs are relatively healthy. , The researchers ... treat pulmonary hypertension and Viagra for erectile dysfunction ... help them identify the root of the blood vessel ... , "We want to understand why these patients have ...
(Date:9/2/2014)... there might be a new salve to dominate medicine cabinets ... lowly salamander. Salamanders may not be the cuddliest of animals, ... of seriously damaged body parts. Now, a new report published ... Journal , identifies a small protein (called a "peptide") ... to unlocking the secret of this amazing wound healing trick ...
(Date:9/2/2014)... of Nuclear Medicine and Molecular Imaging (SNMMI) is pleased ... Fellowship. This two-year fellowship, founded in 2008 by the ... Kanji Torizuka, MD, PhD, is designed to provide extensive ... and molecular imaging for Japanese physicians in the early ... proud to sponsor the Wagner-Torizuka Fellowship. This program honors ...
Breaking Medicine News(10 mins):Health News:Molecular Diagnostic Market: Global Factors and Perspectives by Transparency Market Research 2Health News:Molecular Diagnostic Market: Global Factors and Perspectives by Transparency Market Research 3Health News:Molecular Diagnostic Market: Global Factors and Perspectives by Transparency Market Research 4Health News:REMIND-A-CAP™ , A New York City Based Company Invents Groundbreaking Prescription Cap to Curb Non-Adherence 2Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 2Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 3Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 4Health News:Salamander skin peptide promotes quick and effective wound healing in mice 2Health News:SNMMI 2014-2016 Wagner-Torizuka Fellowship recipients announced 2
... moms have lower rates of depression than their stay-at-home counterparts, ... at greater risk for depression, suggests new research to be ... Association. The study shows that working mothers who ... be blended with relative ease showed higher levels of depression ...
... Paper money worldwide is contaminated with the potentially toxic chemical ... is used to make some plastics and consumer products such ... that BPA is an endocrine disruptor, which means that it ... to a number of health problems. Researchers analyzed 156 ...
... Aug. 19 (HealthDay News) -- Some patients do dream while ... still have a form of consciousness about themselves and the ... electroencephalography (EEG) to compare the structure of sleep in 11 ... five in a vegetative state (unresponsive wakefulness). "We used ...
... can reduce the risk of strokes as well as heart ... System neurologists caution that statins may not be appropriate for ... The article, by Dr. Murray Flaster and colleagues, appears in ... Neurotherapeutics . , A landmark 2006 study known as SPARCL, ...
... , THURSDAY, Aug. 18 (HealthDay News) -- A calcium ... to provide insight into the likelihood that certain patients at ... or stroke, researchers say. The test to detect ... take cholesterol-lowering drugs to reduce their cardiovascular risks, the study ...
... For better or for worse, in sickness and in ... associates marriage with reducing unhealthy habits such as smoking, ... However, new research is emerging that suggests married straight ... intimate relationships may pick up each other,s unhealthy habits ...
Cached Medicine News:Health News:Less depression for working moms who expect that they 'can't do it all' 2Health News:Paper Money Worldwide Tainted With BPA: Study 2Health News:People Appear to Dream While in Minimally Conscious State 2Health News:Cholesterial drugs can reduce the risk of stroke, but aren't for everyone 2Health News:Test for Calcium Buildup May Spot Heart Attack, Stroke Risk 2Health News:Long-term, intimate partnerships can promote unhealthy habits 2Health News:Long-term, intimate partnerships can promote unhealthy habits 3
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
The Ultra HDL (UHDL) assay is used for the quantitation of high density lipoprotein (HDL) cholesterol in human serum or plasma....
... A histological embedment block ... This file system incorporates ... embedment block protection, simplified ... error and facilitation of ...
... The first instrumentation ... efficiently manage the ... Proven technology automatically ... collates cassettes sequentially. ...
Medicine Products: